Novo Nordisk released full results from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity lower their body mass index. The company announced the results on Monday.
Among children who stayed on treatment, Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks. BMI fell 17.4% in the Wegovy group and rose 2.2% in the placebo group. When all children were counted, including those who stopped treatment, the estimated reduction was 16.2 percentage points more than placebo. All 167 children also received lifestyle changes, including a reduced-calorie diet and more physical activity.
Dr. Andrea Traina, Novo's medical director lead of obesity, said the disease imposes "a very significant disease burden in this very young patient population." Novo said the drug's safety and tolerability in children were consistent with its adult trials, and it observed no safety concerns related to growth or puberty.
Wegovy is already approved for obesity in children 12 and older. No medications are currently approved for children under 12. More than 40% of treated children were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment. Novo first shared that result in September.
Traina said the two-year study does not show whether earlier treatment changes the long-term course of obesity, or what treatment and maintenance would look like as children grow up. She called this "an evidence gap" and pointed to future research.